Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 10/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL676509 | 0.86 | DPP4 (0.39) | DPP4PDE2APDE1BPDE4D | |
| SCHEMBL675577 | 0.81 | GRM2 (0.42) | — | |
| SCHEMBL678944 | 0.81 | PDE1B (0.36) | PDE2APDE1BPDE4D | |
| SCHEMBL676897 | 0.81 | MAOB (0.38) | PDE2APDE1BPDE4D | |
| SCHEMBL676380 | 0.81 | PDE1B (0.49) | PDE2APDE1BPDE4D | |
| SCHEMBL680616 | 0.79 | PDE1B (0.44) | PDE2APDE1BPDE4D | |
| SCHEMBL676325 | 0.77 | DPP4 (0.37) | USP1DPP4CYP3A4HCRTR2PDE2A | |
| SCHEMBL680003 | 0.76 | USP1 (0.48) | USP1DPP4CHRM1PDE2APDE1B | |
| SCHEMBL676450 | 0.76 | PDE1B (0.52) | PDE2APDE1BPDE4D | |
| SCHEMBL15943438 | 0.75 | PDE1B (0.38) | PDE2APDE1BPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487527-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150119370-A1 | Organic Compounds | LI PENG (US) | 2015-04-30 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859564-B2 | Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 | INTRA-CELLULAR THERAPIES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2367430-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2014-08-13 | — | — | EP | disclosed |
| EP-2367430-B1 | ORGANIC COMPOUNDS | INTRA CELLULAR THERAPIES INC (US) | 2014-08-13 | — | — | EP | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
| US-20110281832-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281832-A1 | ORGANIC COMPOUNDS | CYP2C9, CYP2C19, CYP3A4 | USP1 4645/4885DPP4 99/4885CHRM1 4026/4885 |
| US-20150119370-A1 | Organic Compounds | CYP2C19, CYP2C9, CYP3A43 | USP1 3856/4885DPP4 1117/4885CHRM1 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.